Role of genomic profiling in the management of intermediate-risk prostate cancer

Описание: Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses novel tools for the management of intermediate-risk prostate cancer, including magnetic resonance imaging (MRI) and genomic profiling which can provide additional information to traditional pathological approaches. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.